Multiplex Test Panel for binx io® Point-of-Care Platform
Positioned to Radically Reduce Time to Treatment, Expand Access to Care
May 1, 2019 (BOSTON, MA) – Binx Health, the pioneer in anywhere care today announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval. The new multiplex test works with the binx io platform, delivering a laboratory-quality result in about 30 minutes, creating a new model for “see-and-treat” care for two of the most prevalent Sexually Transmitted Infections (STIs) globally.
More than one million STIs are acquired worldwide every day with chlamydia and gonorrhea representing two of the most prevalent STIs globally. Recent data released by the European Centre for Disease Prevention and Control (ECDC) notes a striking rise in the cases of gonorrhea – up 17% between 2016 and 2017 across the reporting EU/EEA countries, with some countries noting year-over-year spikes of more than 40%. Likewise, in the United States, infection rates have risen an astonishing 67% since 2013, with rates continuing to be highest in the 20-24 year-old age group in both males and females.
Today, the majority of CT/NG tests are sent to central laboratories, meaning there is often a multi-day waiting period from first visit to treatment, during which time patients may continue to spread infection, with up to 40% of positive patients never returning for treatment. binx is positioned to radically change this paradigm, enabling patients and consumers to leave a retail pharmacy, primary care office, clinic, urgent care facility or any other brick-and-mortar location, with treatment in hand in a single visit. The binx io platform is designed for ease-of-use, enabling non-laboratory-trained users to run a test with the same accuracy as a central lab test, making it ideal for use in a variety of medical and consumer settings.
“Achieving a 30-minute diagnostic turnaround time for the two most common STIs is a major public health breakthrough,” explains Howard Heller, MD MPH, binx’ Chief Medical Officer. “Rapid results equal rapid, appropriate treatment. With this new panel we can offer not just same day, but same visit testing and treatment, eliminating an immense barrier to care and cure. We are also pleased to have completed our US multi-center study for these important tests for submission to FDA for 510(k) clearance.”
“Modern healthcare delivery requires tools that meet consumers needs where they live, work and shop,” said Jeffrey Luber, binx’ Chief Executive Officer. “Doing this effectively means delivering fast, accurate, cost-effective solutions at brick-and-mortar locations, as well as physician-ordered, medical guideline-based testing online, that work to bring consumers from “worry to well” in the locations most convenient for them. Healthcare is increasingly moving to retail and online locations and binx is the only company with solutions for the full continuum of convenient care wherever consumers find themselves. Through scientific rigor, guideline-based testing, and an “anywhere” mindset that puts the consumer at the center of all we do, today we embark on a path to deliver omnichannel, high quality care in family health, starting with young people and STI’s as our launching point.”
About binx health
binx health is the pioneer in convenient care for consumers where they live, work and shop. We do this with (1) proprietary, rapid desktop PCR instruments for retail pharmacy, urgent care, primary care, health centers, and other brick-and-mortar locations with a healthcare mission where onsite, on demand testing and rapid results on par with central lab testing, are paramount, and (2) mobile solutions for at-home, physician-ordered testing that aim to bring consumers from “worry-to-well” in the palm of their hands. Starting with sexually-transmitted infections, we aim to help reverse trends of rising infection among young people, and moving into broader family health through the expansion of our point-of-care and at home offerings. binx investors includes financial investors, Johnson & Johnson Innovation, Novartis Venture Fund, LSP Venture Capital, BB Biotech, RMI Investments and Southwest Ventures Fund and strategic investors, Consort Medical (whose wholly owned subsidiary Bespak are the makers of the company’s low-cost, proprietary multi-plex cartridges) and China-based Wondfo Biotech.
LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, LSP’s management has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over €2.0 billion ($2.3 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s leading life sciences investors. LSP also invests in public companies through its Euronext-listed LSP Life Sciences Fund (Bloomberg: LSP NA). For more information, please visit www.lspvc.com
Dr. Joachim Rothe
Managing Partner LSP
+49 89 120 850 90
 WHO Key facts 28 Feb 2019
Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
Gift, Thomas L. et al. Sex Tran Dis: April 1999 - Volume 26 - Issue 4 - p 232–240« back to overview